Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer

Inclusion Criteria

• •History of any size adenoma, known adenoma on present exam, or colon cancer within the last 6 years
• •Scheduled for colonoscopy
• •Ability to understand and the willingness to sign a written informed consent document
• •Willingness to forego PEG laxative during the study period; if the patient has been on a consistent dose of non-PEG laxative for 90 days prior to study entry, the participant may continue those laxatives; participants must agree to restrict additional laxative use to the rescue medication (bisacodyl) provided
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (equivalent to Karnofsky \>= 70%)
• •Leukocytes \>= 3,000/uL
• •Absolute neutrophil count \>= 1,500/uL
• •Platelets \>= 100,000/uL
• •International normalized ratio (INR) =\< 1.5
• •Total bilirubin =\< 1.5 X institutional upper limit of normal (ULN)
• •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 1.5 X institutional ULN
• •Estimated glomerular filtration rate (eGFR) \> 45
• •Blood urea nitrogen (BUN) \< 40
• •Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; restricting intercourse to a surgically sterilized partner; abstinence) for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
• •If patients are on a dose of cardioprotective aspirin, they must have been on a stable dose for three months prior to colonoscopy and agree to remain at that dose for the six months duration of the study; in addition, patients must agree to limit therapeutic nonsteroidal anti-inflammatory drug (NSAID) use (e.g. pain relief) to no more than 30 cumulative days during the six month duration of the trial